Drugs Market Research Reports & Industry Analysis

... . “US Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to US orphan drug market: US Orphan Drug Market Overview Orphan Drug Designation Criteria Market Specific Reimbursement Policy & Regulatory Framework US Orphan Drug ...

... . “Global Radiopharmaceuticals Market Insight” Report Highlights Global Radio Pharmaceuticals Market Overview by Region arget Patient Base by Region Radiopharmaceuticals Market Regulation for US, Europe & Canada Radioisotopes Used in Radiopharmaceuticals Radiopharmaceutical Clinical Pipeline Insight ...

... Pipeline Analysis The report entitled Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more ... arising from new site-specific and from polymer/nanoparticel-based conjugation systems and the most promising new payloads for ADCs. ...

... start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace ... , controls, calibrators and others. “2014 Analysis of the Global Drugs of Abuse Testing Market” is a unique study designed to help current suppliers and ...

... / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase: Research: 19 Preclinical: 49 Clinical: 1 Phase-I: 25 Phase-I/II: 2 Phase-II: 26 Phase-II/III: 2 Phase-III: 5 Preregistration: 2 Marketed: 10 Unknown: 1

... for Clinical Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Europe Parkinson’s Disease Drug Pipeline by Clinical Phase: Research: 12 Clinical: 26 Phase-I: 14 Phase-I/II: 2 Phase-II: 6 Phase-II/III: 1 Phase-III: 3 Preregistration: 1 Marketed: 18

... Trial Owner / Originator/ Licensee/Collaborator Administrative Route Drug Class ATC Codes Number of Skin Cancer Drug in Pipeline by Clinical Phase: Research: 3 Preclinical: 29 Clinical: 5 Phase 0: 1 Phase-I: 29 Phase-I/II: 18 Phase-II: 41 Phase-III: 13 Registered: 4 Marketed: 18 Unknown: 1

... for the pharma companies in their every-day decision making. “Japan Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ... to identify and analyze the available investment opportunity in the Japan cancer drug market based upon development process. Following parameters for ...

... identify and analyze the available investment opportunity in the Europe lung cancer drug market based upon development process. Following parameters for ... drug profile in development phase are covered in “Europe Lung Cancer Drug Pipeline Analysis” research report: Drug Profile Overview Alternate Names for ...

... in the Europe orphan designated drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Europe Orphan Drug Pipeline Analysis 2014” research report: Drug Profile Overview Active Indication ...

... pace of growth is not being reported in the area of development of drugs and therapies for treating cancers. The report also predicts that the ... analysis in the diagnosis and treatment of various types of cancer, clearing the path for personalized medicine towards becoming a common expression associated with ...

... Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical ... also received clinical approval issued by SFDA in September 2013. Global and China Insulin Industry Report, 2013-2017 mainly covers the ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

... markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others. “ ...

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

... (LMTX), MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5 view points ... Alliances in Alzheimer’s Disease Drug Market B. Licensing Agreement in Alzheimer’s Disease Drug Market C. Collaboration Deal in Alzheimer’s Disease Drug Market D. Merger & Acquisition ...

... and cure to diabetes become more difficult. The prevalence rate of diabetes in China increased from less 1% in 1980 to about 5.5% in 2022, 11% in 2013, which become the ... . The CAGR in 2009-2013 exceeded 17%. CRI estimates the CAGR of China antidiabetic drug market size will keep 15%. For global pharmaceutical ...

... high cost of orphan drugs. International and regional regulations are also hurdles to be overcome, despite harmonisations efforts by agencies. In Market Access for Orphan Drugs: Assessing the Global Landscape, FirstWord goes around the world to lay bare the market access issues affecting orphan drug developers in the ...

This 549-page report presents an overview of the clinical significance and market needs for major current and emerging NAT assays, as well as ... assessments of current and emerging suppliers of nucleic acid testing products, including their sales, product portfolios, marketing tactics, technological know-how, ...

... vitamin D and analogues, and calcitonins always took up above 98% shares of China osteoporosis drug market. The market share of bisphosphonates increased at the ... global pharmaceutical enterprises, they will find huge market opportunities in China. Through this report, the readers can acquire the following ...

... sales forecasts for drugs of abuse procedures by market segment: Physician Offices/Group Practices Emergency Rooms Ambulatory Care Centers Analysis of drugs of abuse procedures Competitive Assessments Assessments of major POC suppliers and emerging market entrants, including their sales, product ...

... (test volumes, sales forecasts, supplier shares) $5,500. This new 318-page report from Venture Planning Group contains 68 tables and provides analysis of the global drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic ...

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the French drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the Italian drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the Japanese drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the Spanish drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 262-page report from Venture Planning Group provides a comprehensive analysis of the US drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

... volumes, sales forecasts, supplier shares) $5,500. This new 313-page report from Venture Planning Group contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and ...

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the French therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

This new 249-page report from Venture Planning Group provides a comprehensive analysis of the German therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the Italian therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the Japanese therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

This new 249-page report from Venture Planning Group provides a comprehensive analysis of the Spanish therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 249-page report from Venture Planning Group provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and sales ...

This new 291-page report from Venture Planning Group provides a comprehensive analysis of the European therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers. The report provides test volume and ...

... annual statistics published, an estimated 201,144 people in the United States were diagnosed with lung cancer. This figure included 107,164 men and ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Lung Cancer Drug Pipeline Analysis ...

... that the US would witness a modest increase in the prevalence of the disease, mostly as a result of the country having already reached epidemic proportions ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Colorectal Cancer Drug Pipeline ...

... in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. ... drug market based upon development process. Following parameters for each drug profile in development phase are covered in “US Parkinson’s Disease Drug Pipeline Analysis ...

... location. “Global RNAi Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed based upon RNAi technology. ... Drug market based upon development process. Following parameters for each drug profile in development phase are covered in “Global RNAi Drug Pipeline ...

... from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the ... increasing, thus increasing the profit margins in the future. “US Orphan Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various ...

... drugs and treatment. The most lucrative markets for infertility drugs are the emerging nations such as India, Brazil, China and Mexico, ... pool of people being affected by lifestyle diseases, thus leading to infertility. “Global Infertility Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the ...

... patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group ... drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report: Drug Profile Overview Alternate Names for Drug ...

... to identify and analyze the available investment opportunity in the HIV Infection drug market based upon development process. Following parameters for each drug profile in clinical development phase are covered in “Global HIV Infection Drug Pipeline Analysis” research report: Drug ...

... observed that almost 1 in 8 people coming under the 65+ age group are patients of Alzeimer’s disease. Amongst the population in the 80+ age group, almost ... market based upon development process. Following parameters for each drug profile in development phase are covered in “US Alzheimer Drug Pipeline Analysis” ...